Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 21 and up

Intrathecal morphine and urinary retention after revision knee replacement

Official title: Post-Operative Urinary Retention on Revision Knee Arthroplasty: the Role of Intrathecal Morphine

Run by University of Toronto · NCT07050277 · Data updated 2026-11-12

This study will see if adding a small dose of spinal (intrathecal) morphine for adults having revision knee replacement lowers early pain but raises the chance of needing a urinary catheter.

Quick facts

PhasePhase 3
Study typeInterventional
Ages21 Years and up
SexAll
Enrollment50 (estimated)
SponsorUniversity of Toronto
Academic / other
Locations1 site (Toronto, Ontario)
StatusRecruiting
StartedJune 24, 2025
Main results expectedJuly 1, 2027
Study endsAugust 1, 2027
Registry record updatedDecember 29, 2025
Trial IDNCT07050277 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults older than 21 having unilateral, non-infected revision total knee arthroplasty, ASA physical status I–III, BMI under 45, without recent opioid use above the protocol threshold, and able to consent in English are ideal candidates.

Probably not a fit

Patients with infected revisions, recent or current high-dose opioid use, contraindications to neuraxial anesthesia or peripheral nerve blocks, pregnancy, or who cannot attend the Toronto surgical site are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults undergoing unilateral, non-infected revision total knee replacement will be assigned to spinal anesthesia with intrathecal morphine or to spinal anesthesia without intrathecal morphine. All participants will receive a standardized multimodal analgesic plan including single-shot and continuous adductor canal block (CACB) and a single-shot IPACK block, plus systemic non-opioid analgesics and rescue opioids as needed. The trial will measure rates of postoperative urinary retention (POUR) and pain scores in the immediate postoperative period. Secondary outcomes include opioid consumption, common opioid-related adverse effects (nausea, pruritus, respiratory depression), and length of hospital stay.

Why it matters

Potential benefit: If positive, the results could show whether intrathecal morphine gives better early pain control after revision knee replacement while clarifying the risk of urinary retention to help tailor anesthesia choices.

How similar studies have gone: Prior studies in lower-limb and abdominal surgery have shown intrathecal morphine reduces early postoperative pain and opioid needs but is also linked to higher rates of urinary retention and opioid-related side effects.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Non pregnant patients undergoing unilateral non infected rTKA surgery;
* Older than 21 years of age, with American Society of Anesthesiologists (ASA) physical status I-III;
* With no alcohol or drug dependency history;
* With sufficient understanding and co-operation about the usage of a perineural catheter for pain management; body mass index (BMI) under 45;
* With no allergy to medications used in the study protocol (bupivacaine, lidocaine, ropivacaine, midazolam, propofol, ketamine, morphine, hydromorphone, fentanyl, acetaminophen, celecoxib, ondansetron, dexamethasone, tranexamic acid);
* No current or recent use of opioids (within the last 2 weeks) in an average oral morphine equivalent (OME) of 20 mg/day or higher;
* With no contra-indications for neuraxial anesthesia, IPACK block, ACB and adductor canal catheter insertion;
* Who speak and understand the English language;
* Who agrees to participate on this study through the signature of the consent form.

Exclusion Criteria:

* Patients will be excluded of the study if they have a failed spinal anesthesia and needs for a conversion to general anesthesia;
* If peripheral nerve blocks are not possible to be performed due to technical difficulties;
* If during patient's care a deviation of the protocol occurs;
* If CACB catheter has issues on its function, disconnects or exteriorizes within the first 48 hours of infusion;
* Or if patient decides to withdraw from the study.

Where it's running

  • Mount Sinai Hospital
    Toronto, Ontario, Canada
    Recruiting

Study contacts

  • Principal investigator: Hermann dos Santos Fernandes, MD, PhD — Department of Anesthesia and Pain Management, Mount Sinai Hospital Assistant
  • Study coordinator: Hermann dos Santos Fernandes, MD, PhD
  • Email: hermann.dossantosfernandes@sinaihealth.ca
  • Phone: 416-586-5270

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.